Abstract: The present invention discloses a compound represented by the following Formula (I) and a pharmaceutically acceptable salt thereof. The compound improves the THR? selectivity while maintaining good THR? agonistic activity, thereby improving properties of the finished drug.
Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.
Type:
Grant
Filed:
March 1, 2018
Date of Patent:
August 3, 2021
Assignee:
Assembly Biosciences, Inc.
Inventors:
William W. Turner, Jr., Leping Li, Simon Nicolas Haydar, Mark G. Bures, Roopa Rai, Samson Francis, Lee D. Arnold
Abstract: Compounds that inhibit p38? MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.
Type:
Grant
Filed:
May 11, 2020
Date of Patent:
August 3, 2021
Assignee:
University of Maryland, Baltimore
Inventors:
Paul S. Shapiro, Alexander D. Mackerell, Jr., Jeffrey D. Hasday, Steven Fletcher
Abstract: The present invention provides novel compounds of formula (Ia) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
Abstract: The present invention provides an improved process for the preparation of Deferasirox of Formula-I substantially free from ‘hydrazino impurity’ by the condensation of 2-(2-hydrophenyl)-4H-1,3-benzoxazin-4-one of Formula-IV with 4-hydrazino benzoic acid of Formula-V in a polar solvent.
Abstract: A compound or its acid addition salt of the general formula (I), wherein R1 represents phenyl substituted with one or two substituents selected from the group consisting of halogen and C1-C3 alkoxyl, or 6-membered heteroaryl with 1 or 2 nitrogen atoms, which is unsubstituted or substituted with a substituent selected from the group consisting of —NH2, halogen, alkyl C1-C4, alkoxyl C1-C3, and 6-membered heterocyclyl comprising 1 or 2 heteroatoms selected from the group consisting of N and O. The compound has the activity of kinase JAK1/JAK3 inhibitor and can find use in the treatment of chronic inflammatory and autoimmunological diseases.
Type:
Grant
Filed:
May 10, 2018
Date of Patent:
July 27, 2021
Assignee:
Celon Pharma S.A.
Inventors:
Michal Mroczkiewicz, Bartosz Stypik, Anna Bujak, Krzysztof Szymczak, Pawel Gunerka, Krzysztof Dubiel, Maciej Wieczorek, Jerzy Pieczykolan
Abstract: The present disclosure relates to novel crystalline forms of ARN-509 (structure shown in formula I), processes for preparation of the novel crystalline forms, pharmaceutical composition of the novel crystalline forms, and uses of the novel crystalline forms for preparing drug products of androgen receptor antagonists and for treating prostate cancer. The crystalline forms of ARN-509 provided by the present disclosure have one or more improved properties compared with the prior art, and is of great value to the future optimization and development of drugs.
Abstract: Novel cinchona alkaloid compounds have been synthesized and discovered to have potent cytotoxic activity against cancer cells both in vitro and in vivo. Cinchona alkaloids, including trimeric cinchona alkaloids as well as their polymers can be used as catalysts of complex chemical reactions in organic chemistry, for example for the enantioselective desymmetrization of cyclic anhydrides, asymmetric synthesis of amino acids (Ayyanar Siva, Eagambaram Murugan. Synthesis 2005; 17:2927-2933; Hyeung-geun Park et al. Tetrahedron Letters, Volume 42, Issue 28, 2001, Pages 4645-4648; Shohei Takata et al., RSC Adv., 2016, 6, 72300-72305; Masud Parvez et al., Macromolecules 2014, 47, 6, 1922-1928; Marcelli, T. 2007, UvA-DARE (Digital Academic Repository). https://pure.uva.nl/ws/files/4416997/52576_marcelli_thesis.
Abstract: The present invention relates to: a process for preparing 3,7-bis-(dimethylamino)-phenothiazin-5-ium bromide or chloride; a method of converting 3,7-bis-(dimethylamino)-phenothiazin-5-ium bromide to 3,7-bis-(di-methylamino)-phenothiazin-5-ium chloride; and the purification of 7-bis-(di-methylamino)-phenothiazin-5-ium chloride by crystallization from aqueous solution of hydrochloric acid, leading to a pharmaceutically acceptable 3,7-bis-(di-methylamino)-phenothiazin-5-ium chloride (methylthioninium chloride, methylene blue, MTC) of formula I below reported.
Type:
Grant
Filed:
March 15, 2018
Date of Patent:
July 13, 2021
Assignee:
MIKROCHEM SPOL. S R.O.
Inventors:
Daniela Benadiková, Juraj Cech, Erik Juhás, Vladimír Oremus, Vendel {hacek over (S)}mahovský
Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
Type:
Grant
Filed:
August 14, 2020
Date of Patent:
July 13, 2021
Assignee:
Incyte Corporation
Inventors:
Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
Abstract: The present disclosure relates to 1,3,5-dioxazine derivatives of formula (I) capable of reducing or eliminating hydrogen sulfide and other objectionable sulfides from oil field produced hydrocarbon fluids such as petroleum, fuel oil, gasoline, diesel, liquid propane, liquid butane, an aquaculture and production/processing of syngas/natural gas. The present disclosure further provides a method for preparing 1,3,5-dioxazine derivatives of formula I, and a method for scavenging sulfur-based species including, but not limited to hydrogen sulfide or alkyl/aryl mercaptans from a medium.
Abstract: Disclosed in the present invention are a compound represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt, and applications thereof in the preparation of drugs for treating HBV-related diseases.
Abstract: The present invention relates to a crystal of cephalosporin intermediate 7?-methoxy cephalothin (I) and a method for preparing same. The crystal of 7?-methoxy cephalothin (I) undergoes Cu-Ka radiation and X-ray powder diffraction expressed in terms of angle 2?; the crystal of 7?-methoxy cephalothin (I) has characteristic absorption peaks at positions of 7.34°±0.20°, 12.71°±0.20°, 14.25°±0.20°, 14.68°±0.20°, 16.52°±0.20°, 17.99°±0.20°, 19.98°±0.20°, and 22.69°±0.20°. The crystal of 7?-methoxy cephalothin provided by the present invention is easy to prepare. Related test data shows that the crystal of 7?-methoxy cephalothin has high purity, low impurity content, and good stability. The preparation cost is low, the preparation method is simple to operate, conditions are mild and easy to control, and crystals of 7?-methoxy cephalothin can be obtained stably. The invention is applicable to industrial production.
Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.
Type:
Grant
Filed:
November 15, 2019
Date of Patent:
June 29, 2021
Assignee:
WisTa Laboratories Ltd.
Inventors:
Claude Michel Wischik, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
Abstract: Disclosed herein are pyrozolo-pyrimidin-amino-cycloalkyl compounds, analogs thereof, pharmaceutical compositions comprising thereof and therapeutic uses therefor.
Type:
Grant
Filed:
June 4, 2019
Date of Patent:
June 29, 2021
Assignee:
RAPT THERAPEUTICS, INC.
Inventors:
Minna H. T. Bui, Adrian O. Dukes, Xinping Han, Dennis X. Hu, Jeffrey J. Jackson, Yoo Min Ko, Paul R. Leger, Anqi Ma, Jack Maung, Andrew A. Ng, Akinori Okano, Omar Robles, Grant Shibuya, Hunter P. Shunatona, Jacob B. Schwarz, Anton A. Shakhmin, David J. Wustrow, Mikhail Zibinsky
Abstract: This invention relates to new benzazepine carboxamide compounds of the formula wherein X and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR8 agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
Abstract: The present invention discloses a compound represented by the following Formula (I) and a pharmaceutically acceptable salt thereof. The compound improves the THR? selectivity while maintaining good THR? agonistic activity, thereby improving properties of the finished drug.
Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
Type:
Grant
Filed:
June 17, 2020
Date of Patent:
June 15, 2021
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Thomas Woltering